Press Releases All News 2019 2018 2017 2016 2015 2014 Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression October 15, 2019 Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15 October 14, 2019 Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market October 10, 2019 Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market October 8, 2019 Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market September 27, 2019 Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression July 29, 2019 Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles June 3, 2019 Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting May 31, 2019 Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results April 16, 2019 Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations April 3, 2019 1 2 3 4 5 6 7 8 9 10 ...13 Next »
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression October 15, 2019
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15 October 14, 2019
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market September 27, 2019
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression July 29, 2019
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting May 31, 2019
